Back

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.

7 April 2024 (08:30 - 15:00)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Science: devices Oral Anticoagulation EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Julius Nikorowitsch

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

9 More presentations in this session

Presentation thumbnail
Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease
Doctor E. Pisano (Lecce, IT)
Slides Video
Presentation thumbnail
Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion
Doctor N. Varma (Cleveland, US)
Slides Video
Presentation thumbnail
Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion
Doctor S. Al-Khatib (Durham, US)
Slides Video
Presentation thumbnail
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial
Doctor W. McIntyre (Hamilton, CA)
Slides Video
Presentation thumbnail
Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion
Professor T. Potpara (Belgrade, RS)
Slides Video

Access the full session

Session thumbnail
Late-Breaking Science: devices
Video

The Event

Event poster

EHRA 2024

7 April - 9 April 2024
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources